Study finds participants saw reduction in depressive symptoms as researchers welcome ‘promising’ resultsA phase II clinical trial has found dimethyltryptamine (DMT), one of the psychoactive components traditionally used in the Amazonian psychedelic ritual ayahuasca, might be a promising therapy for depression.The psychedelic pharmaceutical company Small Pharma (now Cybin UK) sponsored and designed the trial, which was led by Dr David Erritzoe, a psychiatrist and neuroscientist at Imperial College London. The results were published in Nature this month. Continue reading...
Več na: https://www.theguardian.com/science/2026/feb/25/ayahuasca-component-dmt-psychedelic